UBS analyst Paul Gong downgrades NIO (NYSE:NIO) from Buy to Neutral and lowers the price target from $32 to $13.
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here’s How Much You’d Have Now
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.
